CASE SERIES

Dupilumab for the treatment of alopecia areata in children with atopic dermatitis

Sung Kyung Cho, BA,a and Brittany G. Craiglow, MD,b,c
Dallas, Texas and New Haven and Fairfield, Connecticut

Key words: alopecia areata; alopecia totalis; alopecia universalis; atopic dermatitis; children; dupilumab; pediatric.

INTRODUCTION

Alopecia Areata (AA) often co-occurs with atopic dermatitis (AD), with up to one-third of patients with AA also affected by AD.1,2 Dupilumab, an interleukin 4 receptor antagonist, Food and Drug Administration-approved for the treatment of moderate-to-severe AD in patients 6 years and older, has begun to receive some interest for a potential role in the treatment of AA. While some case reports and series have demonstrated improvement of AA with dupilumab,3-6 there are also reports of patients developing new-onset hair loss during treatment.7-9 Given that the treatments for AA are limited, especially for children, dupilumab represents an intriguing therapeutic option.

Here, we present 6 pediatric patients (4 girls and 2 boys) aged 7 to 12 years with both AA and AD treated with dupilumab.

CASE SERIES

Patient clinical characteristics and response to treatment are detailed in Table I. All patients had moderate-to-severe AD starting in infancy, and 4 patients had other atopic comorbidities, including asthma and food allergies. The median age of onset of AA was 5.5 years (standard deviation, 2.9 years) with a median initial severity of alopecia tool score of 62.5 (range, 25-100). All patients had shown suboptimal response to multiple prior therapies for both AA and AD. Four patients received concomitant treatment for AA along with dupilumab.

Five of 6 patients demonstrated improvement in AA. Patient 1 had a 73% improvement in the severity of alopecia tool score on dupilumab monotherapy (Fig 1), while 4 patients (patients 2, 3, 4, and 5) had complete regrowth, 3 of whom received concurrent treatment for AA. Patient 6 did not have any regrowth despite being on dupilumab for 16 months and concomitant oral minoxidil and topical corticosteroids. One patient (patient 3) experienced mild, transient conjunctivitis controlled with corticosteroid and antihistamine eye drops. One patient (patient 2) discontinued treatment after 6 months secondary to severe anxiety related to injections; dupilumab was otherwise well tolerated by all the patients.

DISCUSSION

While the sample size is small and some patients received concurrent AA treatments, these results contribute to the small but growing body of literature that dupilumab may be an effective treatment option for AA among a subset of patients with AD. While the mechanism of action of dupilumab in AA remains unknown, it has been hypothesized that some patients with AA and AD may exhibit more Th2 skewing.10,11 Prior reports have suggested that those with more severe and long-standing AD may be more likely to experience hair regrowth with dupilumab; however, that is not a trend that we observed.5,10 Additional studies will be necessary.

From the Department of Dermatology, University of Texas Southwestern Medical Center, Dallas,a Department of Dermatology, Yale University School of Medicine, New Haven,b and Dermatology Physicians of Connecticut, Fairfield.c

Funding sources: None.
IRB approval status: Not applicable.
Correspondence to: Brittany G. Craiglow, MD, Department of Dermatology, Yale School of Medicine, Dermatology, PO Box 208059, New Haven, CT 06520-8059. E-mail: brittany.craiglow@yale.edu.

JAAD Case Reports 2021;16:82-5.
2352-5126
© 2021 by the American Academy of Dermatology, Inc. Published by Elsevier, Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
https://doi.org/10.1016/j.jdcr.2021.07.015
Table I. Characteristics and outcomes of pediatric patients with AA on dupilumab

| Age at dupilumab initiation (y) | Age of AA onset (y) | Sex | Comorbidities                         | Prior AA therapies | Prior AD therapies | Concomitant AA treatment | Initial AD IGA | Latest AD IGA | Initial SALT | Latest SALT | Duration of therapy (months) |
|-------------------------------|--------------------|-----|--------------------------------------|------------------|------------------|------------------------|----------------|---------------|-------------|-------------|-----------------------------|
| 12                            | 3                  | M   | Asthma, food allergies               | TCS, TM          | TCS, pimecrolimus, tacrolimus | None                  | 4             | 1             | 75          | 20          | 24                          |
| 7                             | 5                  | M   | Asthma                               | TCS              | TCS, tacrolimus, crisaborole | None                  | 3             | 1             | 25          | 0           | 6                           |
| 7                             | 6                  | F   | Food allergies                       | TCS, ILTAC       | TCS, tacrolimus          | Pulsed prednisone 5 mg/kg monthly x 6 doses, OM | 4             | 1             | 90          | 0           | 16                          |
| 8                             | 3                  | F   | None                                 | Pulsed prednisone, TCS, anthralin, topical tofacitinib, OM | TCS, tacrolimus, crisaborole | OM, topical tofacitinib | 2             | 0             | 25          | 0           | 6                           |
| 7                             | 6                  | F   | None                                 | TCS, TM, topical tofacitinib | TCS, pimecrolimus | Topical tofacitinib, TM | 2             | 1             | 50          | 0           | 6                           |
| 12                            | 11                 | F   | Food allergies                       | Pulsed prednisone, ILTAC, TCS | TCS, tacrolimus          | OM, TCS               | 3             | 1             | 100         | 100         | 16                          |

AA, Alopecia areata; AD, atopic dermatitis; IGA, Investigator's Global Assessment; ILTAC, intralesional triamcinolone; OM, oral minoxidil; SALT, severity of alopecia tool score, TCS, topical corticosteroids; TM, topical minoxidil.
to further investigate the role of dupilumab for the treatment of AD, including its mechanism and whether certain clinical characteristics may correlate with treatment response. The favorable safety profile associated with dupilumab, coupled with its Food and Drug Administration approval for AD in children as young as 6 years of age, makes it a reasonable option to consider for pediatric patients with AA who have concomitant AD. Combining dupilumab with other AA treatments such as topical corticosteroids, topical Janus kinase inhibitors, and/or topical or oral minoxidil may possibly improve efficacy.

Conflicts of interest

Dr Craiglow has received honoraria and/or fees from Aclaris, Arena Pharmaceuticals, Eli Lilly, Regeneron, Sanofi-Genzyme, and Pfizer. Ms Cho has no conflicts of interest to declare.

REFERENCES

1. Suárez-Fariñas M, Ungar B, Noda S, et al. Alopecia areata profiling shows TH1, TH2, and IL-23 cytokine activation without parallel TH17/TH22 skewing. J Allergy Clin Immunol. 2015;136(5):1277-1287.
2. Mohan GC, Silverberg JI. Association of vitiligo and alopecia areata with atopic dermatitis: a systematic review and meta-analysis. JAMA Dermatol. 2015;151(5):522-528.
3. Penzi LR, Yasuda M, Manatis-Lornell A, Hagigeorges D, Senna MM. Hair regrowth in a patient with long-standing alopecia totalis and atopic dermatitis treated with dupilumab. JAMA Dermatol. 2018;154(11):1358-1360.
4. Smogorzewski J, Sierro T, Compoginis G, Kim G. Remission of alopecia universalis in a patient with atopic dermatitis treated with dupilumab. JAAAD Case Rep. 2019;5(2):116-117.
5. Gruenstein D, Malik K, Levitt J. Full scalp hair regrowth in a 4-year-old girl with alopecia areata and atopic dermatitis treated with dupilumab. J AAAD Case Rep. 2020;6(12):1286-1287.
6. McKenzie PL, Castelo-Soccio L. Dupilumab therapy for alopecia areata in pediatric patients with concomitant atopic dermatitis. J Am Acad Dermatol. 2021;84(6):1691-1694.
7. Mitchell K, Levitt J. Alopecia areata after dupilumab for atopic dermatitis. *JAAD Case Rep.* 2018;4(2):143-144.
8. Flanagan K, Sperling L, Lin J. Drug-induced alopecia after dupilumab therapy. *JAAD Case Rep.* 2019;5(1):54-56.
9. Chung J, Slaught CL, Simpson EL. Alopecia areata in 2 patients treated with dupilumab: new onset and worsening. *JAAD Case Rep.* 2019;5:643-645.
10. Marks DH, Mesinkovska N, Senna MM. Cause or cure? Review of dupilumab and alopecia areata. *J Am Acad Dermatol.* 2019.
11. Kageyama R, Ito T, Hanai S, et al. Immunological properties of atopic dermatitis-associated alopecia areata. *Int J Mol Sci.* 2021;22(5):2618.